| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Clinigen Group plc (LSE: CLIN)
CLIN Technical Analysis
5
| As on 4th Apr 2022 CLIN STOCK Price closed @ 925.00 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 698.82 & Strong Buy for SHORT-TERM with Stoploss of 648.14 we also expect STOCK to react on Following IMPORTANT LEVELS. |
CLINSTOCK Price
| Open | 924.00 | Change | Price | % |
| High | 925.00 | 1 Day | 0.00 | 0.00 |
| Low | 924.00 | 1 Week | 4.00 | 0.43 |
| Close | 925.00 | 1 Month | 3.00 | 0.33 |
| Volume | 539375 | 1 Year | 355.00 | 62.28 |
| 52 Week High 930.00 | 52 Week Low 570.00 | ||||
LSE UK Most Active Stocks
| MIRI | 0.01 | 0.00% |
| PREM | 0.01 | 0.00% |
| UKOG | 0.01 | 0.00% |
| MSMN | 0.03 | 50.00% |
| TRP | 0.03 | % |
| VRS | 0.02 | 100.00% |
| DEMG | 0.02 | -50.00% |
| SMDS | 582.50 | 0.00% |
| DKE | 0.15 | 0.00% |
| NNN | 0.09 | 50.00% |
LSE UK Top Gainers Stocks
LSE UK Top Losers Stocks
| CLIN Daily Charts |
CLIN Intraday Charts |
Whats New @ Bazaartrend |
CLIN Free Analysis |
|
|
CLIN Important Levels Intraday
| RESISTANCE | 926.93 |
| RESISTANCE | 926.31 |
| RESISTANCE | 925.93 |
| RESISTANCE | 925.55 |
| SUPPORT | 924.46 |
| SUPPORT | 924.07 |
| SUPPORT | 923.69 |
| SUPPORT | 923.07 |
CLIN Forecast July 2025
| 4th UP Forecast | 1150.46 |
| 3rd UP Forecast | 1078.15 |
| 2nd UP Forecast | 1033.46 |
| 1st UP Forecast | 988.77 |
| 1st DOWN Forecast | 861.24 |
| 2nd DOWN Forecast | 816.54 |
| 3rd DOWN Forecast | 771.85 |
| 4th DOWN Forecast | 699.54 |
CLIN Weekly Forecast
| 4th UP Forecast | 1046.40 |
| 3rd UP Forecast | 1007.47 |
| 2nd UP Forecast | 983.40 |
| 1st UP Forecast | 959.34 |
| 1st DOWN Forecast | 890.67 |
| 2nd DOWN Forecast | 866.60 |
| 3rd DOWN Forecast | 842.53 |
| 4th DOWN Forecast | 803.60 |
CLIN Forecast2025
| 4th UP Forecast | 1708.42 |
| 3rd UP Forecast | 1457.17 |
| 2nd UP Forecast | 1301.87 |
| 1st UP Forecast | 1146.57 |
| 1st DOWN Forecast | 703.43 |
| 2nd DOWN Forecast | 548.13 |
| 3rd DOWN Forecast | 392.83 |
| 4th DOWN Forecast | 141.58 |
Clinigen Group plc ( LSE UK Symbol : CLIN )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
CLIN Business Profile
Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through Services and Products divisions. The company provides a set of niche and high value services to pharma and biotech clients prior to product launch. It also provides access to critical medicines around the world for patients with unmet needs. In addition, the company provides a portfolio of specialist medicines to service the needs of healthcare professionals and their patients in both licensed and unlicensed markets. Further, it offers Nortriptyline Colonis for the treatment of depressive disorder; Metformin Colonis for the treatment of type 2 diabetes mellitus; Magnesium Chewable Tablets, an oral magnesium supplements for the treatment of patients with chronic magnesium loss; Iloprost, a concentrate for solution for infusion; Glycopyrronium Bromide, an oral solution for the treatment of severe sialorrhoea; Acetylcysteine, an oral solution for the treatment of respiratory disorders associated with thick, viscous, and mucus hypersecretion; Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Proleukin for the treatment of kidney cancer; Imukin that is used in chronic granulomatous disease; Totect, a dexrazoxane product; Foscavir, an anti-virals that work by stopping viruses from multiplying in number; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom. Address: Pitcairn House, Burton Upon Trent, United Kingdom, DE14 2WW
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service